About Aditxt
Aditxt (NASDAQ:ADTX) focuses on developing technologies aimed at improving the health of the immune system through immune mapping and reprogramming. Their innovative approach includes work on desensitization technologies, aiming to reduce harmful immune responses, and the AditxtScore™ platform, which provides a detailed profile of an individual's immune system status. The company's projects revolve around enhancing the body's ability to fight diseases and reducing adverse reactions to external elements, with the objective to bring transformative solutions to immune health on a global scale. Aditxt is dedicated to advancing healthcare through groundbreaking immune health management, striving to mitigate the challenges associated with autoimmune and allergic diseases, as well as improving overall immune health.
Snapshot
Operations
Products and/or services of Aditxt
- Adimune™, a proprietary immune monitoring technology designed to accurately profile an individual's immune system status.
- AditxtScore™ for COVID-19, a comprehensive immune monitoring service specifically for detecting and understanding immunity levels against SARS-CoV-2.
- Development of therapeutic modalities aimed at reprogramming the immune system to induce tolerance in cases of autoimmune diseases and organ transplant rejection.
- Research and partnerships focused on enhancing the scalability and efficacy of immune monitoring technologies for broader infectious and autoimmune diseases.
- Collaboration with leading pharmaceutical and biotech companies to integrate immune profiling technologies into the drug development process, optimizing therapeutic efficacy and safety.
- Engagement in strategic acquisitions and partnerships to expand its portfolio of immune health technologies and services, aiming to become a leader in personalized immune health.
Aditxt executive team
- Mr. Amro A. AlbannaCo-Founder, Chairman, CEO & President
- Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.Co-Founder, Chief Innovation Officer, Secretary & Director
- Mr. Thomas J. Farley CPAChief Financial Officer
- Ms. Corinne D. Pankovcin CPA, M.B.A.Chief Mergers & Acquisitions Officer
- Ms. Rowena AlbannaChief Operating Officer
- Mr. Christopher J. PorcelliGeneral Counsel
- Ms. Jennifer LeeDirector of Human Resources
- Dr. Dolly B. Tyan D(ABHI), Ph.D.Senior Vice President of Clinical Development ? Transplantation
- Mr. Ge Chen M.D., M.S.Senior Vice President of Preclinical Research & Discovery